cell therapy
Market Access/ News/ News/ News/ Oncology
Atara claims first world approval for off-the-shelf T-cell therapy
Phil Taylor
allogeneic, Atara Biotherapeutics, cell therapy, Ebvallo, rare disease
0 Comment
News/ News/ News/ Oncology/ R&D
GSK’s pullback from cell therapy continues as Immatics alliance ends
Phil Taylor
cell therapy, GlaxoSmithKline, Immatics, immuno-oncology, Oncology, partnering, TCR
0 Comment
Market Access/ News/ News/ News/ Oncology
Atara closes on first approval of transplant complication therapy
Phil Taylor
allogeneic, Atara Biotherapeutics, cell therapy, Ebvallo, immuno-oncology, Oncology, Pierre Fabre, tabelecleucel
0 Comment
Roche puts $70m into ArsenalBio’s programmable T-cell platform
Phil Taylor
ArsenalBio, cell therapy, Genentech, immuno-oncology, Oncology, partnering, Roche, solid tumours
0 Comment
News/ News/ Press Releases/ R&D
CapstanTx secures $165 million to deliver precise in vivo cell engineering
Nicole Raleigh
Capstan Therapeutics, CAR-T therapy, cell therapy, in vivo, investment, Lipid Nanoparticles, mRNA, pharma, tLNP
0 Comment
ESMO: TIL therapy improves on Yervoy in melanoma trial
Phil Taylor
cell therapy, ESMO 2022, immuno-oncology, melanoma, Oncology, tumour-infiltrating lymphocytes
0 Comment
Market Access/ Partner content/ Press releases
2nd iPSC-Derived Cell Therapies Summit
jade faulkner
Allogenic, cell therapy, iPSC, Regenerative medicine, stem cell
0 Comment
The Industry’s Largest Event Showcasing iPSC Therapies
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Phil Taylor
cell therapy, M&A, type 1 diabetes, Vertex Pharma, ViaCyte
0 Comment